A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Conditions
Achondroplasia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
QED Investigative Site, San Francisco, California, United States
QED Investigative Site, Aurora, Colorado, United States
QED Investigative Site, Baltimore, Maryland, United States
QED Investigative Site, Columbia, Missouri, United States
QED Investigative Site, Cincinnati, Ohio, United States
QED Investigative Site, Nashville, Tennessee, United States
QED Investigative Site, Madison, Wisconsin, United States
QED Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina
QED Investigative Site, Parkville, Victoria, Australia
QED Investigative Site, Edmonton, Alberta, Canada
QED Investigative Site, London, Ontario, Canada
QED Investigative Site, Ottawa, Ontario, Canada
QED Investigative Site, Montreal, Quebec, Canada
QED Investigative Site, Bron, France
QED Investigative Site, Paris, France
QED Investigative Site, Toulouse, France
QED Investigative Site, Rome, Italy
QED Investigative Site, Bergen, Norway
QED Investigative Site, Oslo, Norway
QED Investigative Site, Singapore, Singapore
QED Investigative Site, Málaga, Spain
QED Investigative Site, Vitoria-Gasteiz, Spain
QED Investigative Site, Bristol, United Kingdom
QED Investigative Site, Glasgow, United Kingdom
QED Investigative Site, London, United Kingdom
QED Investigative Site, Manchester, United Kingdom
QED Investigative Site, Sheffield, United Kingdom
Study leads
QED Therapeutics, Inc. Medical Director, Clinical Development
Study Director
QED Therapeutics